McKesson Q1 FY26: where the revenue came from and where it went
The whole income statement of McKesson for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2025
- Reported
- Aug 6, 2025
Revenue$97.83B
+23% year over year
Gross profit$3.28B
3% margin
Operating profit$1.04B
1% margin
Net profit$0.78B
1% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 97.83 | 100% | +23% |
| U.S. pharmaceutical | 89.95 | 92% | +25% |
| International | 3.74 | 4% | +1% |
| Medical-Surgical | 2.70 | 3% | +2% |
| Prescription technology | 1.43 | 1% | +16% |
| Cost of revenue | −94.55 | 97% | |
| Gross profit | 3.28 | 3% margin | −1pp |
| SG&A | −2.20 | 2% | +0pp |
| Other | −0.05 | 0% | +0pp |
| Operating profit | 1.04 | 1% margin | +0pp |
| Tax | −0.25 | ||
| Net profit | 0.78 | 1% margin | +0pp |
124 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest